Please Find Enclosed Herewith the Scrutinizer Report of 30th Annual General Meeting of the Company
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Boston Bio Systems Limited held its 30th AGM on September 30, 2025 via video conferencing, where all 11 resolutions were passed. Key items approved include adoption of FY25 audited financial statements, re-appointment of Mr. Ghanshyam Gavali as director, appointment of M/s Sunit M Chhatbar & Co as statutory auditor for 5 years (filling the casual vacancy left by the resignation of M/s Nahar V. & Co), his change in designation to Managing Director, and regularisation of Mr. Yash Arun Chaudhary as Non-Executive Director. Shareholders also approved a change in the company's name, alteration in the object clause of the MOA, adoption of new MOA and AOA, and an increase in the company's borrowing limits. Voting turnout was extremely low, with only 174,292 votes polled out of 7,002,200 outstanding shares (about 2.49%), and notably the promoters holding 150,020 shares did not vote. Of the votes polled, roughly 97.58% were in favour across resolutions, with one resolution (appointment of Mr. Chaudhary) receiving 100% approval.
The passing of these resolutions gives the company flexibility to change its name, broaden its business objects, raise additional borrowings, and operate with a new auditor and expanded board — signals of a potential business pivot or restructuring. However, the very low voting turnout and absence of promoter participation suggest limited shareholder engagement, which retail investors should note.